Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
ZUG, Switzerland, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Oculis Holding AG ( Nasdaq: OCS ) ( "Oculis" ) , a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that an update on the DIAMOND Phase 3 program with OCS-01, an OPTIREACH® formulation ...
| Ticker |
Sentiment |
Impact |
|
AON
|
Neutral
|
18 %
|
|
OCS
|
Somewhat Bullish
|
58 %
|
